The effect of topical dorzolamide for macular edema

The effect of topical dorzolamide for macular edema - The effect of topical dorzolamide for macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007453

Enrollment

Registered

2012-03-06

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular edema after vitrectomy

Interventions

Topical dorzolamide was administrated to eye after vitrectomy three times per day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with macular edema after vitrectomy

Exclusion criteria

Exclusion criteria: Any patients with preexisting ocular disease (glaucoma, high myopia, chronic inflammatory, or neoplastic disorders), systemic disorders (diabetes or uncontrolled hypertension), a known lifethreatening disease, or eyes allergic to dorzolamide were excluded.

Design outcomes

Primary

Measure	Time frame
visual acuity, intraocular pressure, central macular thickness, and aqueous flare	—

Countries

Japan

Contacts

Public ContactTakahiro Suzuki

Tokai University School of Medicine Ophthalmology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026